| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
DODAP does not have a specific receptor target. As an ionizable cationic lipid, its primary function is to facilitate the encapsulation and intracellular delivery of nucleic acids by forming lipid nanoparticles that enable endosomal escape. It remains largely neutral at physiological pH and becomes protonated under acidic conditions, such as those encountered during endosomal trafficking.
|
|---|---|
| ln Vitro |
In vitro, DODAP-based LNPs delivered luciferase mRNA to HEK293T cells for 24 hours, though luciferase expression was lower than MC3-LNPs, indicating reduced transfection efficiency. DODAP has been used to encapsulate siRNA, immunostimulatory oligodeoxynucleotides, antisense oligonucleotides, and chemotherapeutic agents.
|
| ln Vivo |
In vivo, DODAP-containing liposomes are used for the delivery of siRNA, immunostimulatory agents, antisense oligonucleotides, and chemotherapeutic agents. The ionizable nature of DODAP (pKa 5.59) allows for pH-dependent charge, facilitating endosomal escape after cellular uptake.
|
| Enzyme Assay |
In vitro liposome formation with DODAP involves dissolving the lipid with other components (e.g., DSPC, cholesterol, PEG-lipid) in ethanol, then mixing with aqueous buffer containing the nucleic acid cargo at controlled pH. The resulting LNPs are characterized for size, polydispersity, and encapsulation efficiency. The pKa is determined using a TNS (2-(p-toluidino)naphthalene-6-sulfonic acid) binding assay. DODAP is slightly soluble in chloroform and methanol.
|
| Cell Assay |
Cellular transfection efficiency of DODAP formulations is assessed in cell lines such as HEK293T. Cells are treated with LNPs encapsulating reporter genes (luciferase or GFP mRNA), and expression is measured after 24 hours. Cytotoxicity is evaluated using standard assays such as MTT or CellTiter-Glo.
|
| Animal Protocol |
In vivo studies involve intravenous administration of DODAP-based LNPs in mice. Tissue distribution, gene expression levels (for mRNA/siRNA cargo), and pharmacokinetic parameters are assessed. DODAP formulations have been evaluated for the delivery of therapeutic nucleic acids in preclinical models.
|
| ADME/Pharmacokinetics |
DODAP is an ionizable cationic lipid with low cytotoxicity. Its pKa of 5.59 allows the lipid to be positively charged at acidic pH (enabling endosomal escape) and neutral at physiological pH (reducing toxicity). Pharmacokinetic properties depend on the LNP formulation.
|
| Toxicity/Toxicokinetics |
DODAP exhibits low cytotoxicity compared to permanently cationic lipids. The ionizable nature of DODAP reduces non-specific membrane disruption and toxicity at physiological pH, while enabling endosomal escape in acidic compartments. Standard safety precautions for handling lipids should be followed.
|
| References |
|
| Additional Infomation |
DODAP (also known as 18:1 DAP) is used as a component in liposomes for encapsulating siRNA, immunostimulatory oligodeoxynucleotides, antisense oligonucleotides, and chemotherapeutic agents. Its ionizable property makes it a valuable tool for nucleic acid delivery research. It has been used in studies for tumor vascular targeting and targeted liposomal delivery.
|
| Molecular Formula |
C41H77NO4
|
|---|---|
| Molecular Weight |
648.05
|
| Exact Mass |
647.585
|
| CAS # |
127512-29-2
|
| PubChem CID |
9895790
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.916g/cm3
|
| Boiling Point |
670.148ºC at 760 mmHg
|
| Flash Point |
359.092ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.476
|
| LogP |
12.078
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
37
|
| Heavy Atom Count |
46
|
| Complexity |
717
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCC/C=C\CCCCCCCC(OCC(OC(CCCCCCC/C=C/CCCCCCCC)=O)CN(C)C)=O
|
| InChi Key |
NYDLOCKCVISJKK-WRBBJXAJSA-N
|
| InChi Code |
InChI=1S/C41H77NO4/c1-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35-40(43)45-38-39(37-42(3)4)46-41(44)36-34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-2/h19-22,39H,5-18,23-38H2,1-4H3/b21-19-,22-20-
|
| Chemical Name |
[3-(dimethylamino)-2-[(Z)-octadec-9-enoyl]oxypropyl] (Z)-octadec-9-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (154.31 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.86 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (3.86 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5431 mL | 7.7155 mL | 15.4309 mL | |
| 5 mM | 0.3086 mL | 1.5431 mL | 3.0862 mL | |
| 10 mM | 0.1543 mL | 0.7715 mL | 1.5431 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
